Background: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease. Methods: The NICOREN multicentre, open-label and randomized study was designed to examine non-inferiority and safety of NAM when compared with sevelamer (SEV) in chronic haemodialysis patients. One hundred patients were randomized to either NAM or SEV treatment for 24 weeks. Serum biochemistry and NAM's main metabolite, N-methyl-2-pyridone-5-carboxamide (2PY), were measured to assess compliance, efficacy and safety. Results: After 24 weeks, we observed a comparable decrease in serum phosphorus in the NAM and SEV treatment arms, from 2.1 6 0.4 to 1.8 6 0.5 and 2.3 6 0.5 to 1.7 6 0.5 mM (P ¼ not significant), respectively. The criterion for non-inferiority was, however, not met due to a more limited number of patients being included than planned. Treatment discontinuation due to adverse events was 1.6 times higher in the NAM than in the SEV group with only 55% of study completers in the NAM arm versus 90% in the SEV arm. Thrombocytopenia was observed in four NAM-treated patients. Serum 2PY levels were comparable at baseline, but increased markedly in the NAM group, but not in the SEV group, at 24 weeks (P < 0.0001). Conclusions: Thus, both drugs are equally effective in lowering serum phosphorus, but patients' tolerance of NAM was largely inferior to that of SEV. Extremely high 2PY levels may contribute to NAM's side effects.
I N T R O D U C T I O N
Hyperphosphataemia is a common complication of late-stage chronic kidney disease (CKD). It is particularly marked in patients receiving dialysis therapy. In CKD, the inability to maintain phosphorus balance contributes to the development of mineral and bone disorder and is associated with an increased incidence of vascular calcification, cardiovascular events and mortality [1] [2] [3] [4] . Key hormones and growth factors involved in the renal handling of phosphorus and calcium include parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), a-Klotho and 25-hydroxyvitamin D (25-OH vitamin D).
Several strategies can be used to manage hyperphosphataemia, including dietary phosphorus restriction, the administration of phosphate-binding agents (including recently introduced novel treatments), effective control of hyperparathyroidism and optimal dialysis strategies in CKD stage 5D patients. Nevertheless, controlling hyperphosphataemia remains challenging, and this complication remains extremely common in late-stage CKD patients. Although phosphate binders are effective in reducing serum phosphorus levels, their long-term effects on clinical outcomes are subject to debate [5] . Since no randomized, controlled study is available showing convincingly that the reduction of high serum phosphorus levels leads to an improvement in hard patient outcomes, there is a clear need for such studies. Another important issue is limited patient acceptance of large amounts of phosphate binders. The discovery and development of new, less bulky drugs for this indication is, therefore, a priority for both medical and economic reasons.
Nicotinamide (NAM), also called niacinamide, appears to be an interesting pharmacological alternative to binder-based approaches in the treatment of hyperphosphataemia [6] . This amide derivative of the water-soluble vitamin B3 inhibits sodium-dependent phosphate co-transport in the renal proximal tubule and in the intestine and thereby can reduce hyperphosphataemia in CKD [7] [8] [9] . A number of clinical studies have shown that NAM reduces hyperphosphataemia in dialysis patients with a lower pill burden [6] . However, these studies were limited by short treatment periods and small sample sizes [6] . Moreover, NAM has never been compared with a commercialized phosphate binder in a large, controlled trial. Furthermore, it has been demonstrated that accumulation of the main metabolite of NAM (N-methyl-2-pyridone-5-carboxamide, 2PY) may have toxic effects, particularly so in CKD patients [10] . Slominska et al. [11] have suggested that accumulation of both NAM and 2PY in the plasma of children with CKD leads to an inhibition of poly(ADP-ribose)polymerase (PARP)-1 activity.
Moreover, there are conflicting findings with regard to the impact of phosphate binders on circulating FGF23 and a-Klotho levels. In fact, some studies have found a decrease in FGF23 with the use of sevelamer (SEV) (especially in dialysis patients [12, 13] ), whereas others failed to observe a change [14, 15] . Recent data have shown a significant increase in soluble a-Klotho levels after 48 weeks of treatment with SEV [12] . The impact of NAM on circulating FGF23 or a-Klotho levels of patients with CKD has not yet been evaluated. Data from a murine model of familial tumoral calcinosis suggest that the administration of NAM decreases intact FGF23 levels [16] .
Hence, we decided to evaluate and compare the effect of NAM with that of SEV on serum phosphorus and the main hormones and growth factors that contribute to its regulation in patients on long-term haemodialysis treatment. The primary objective of the NICOREN study was to evaluate noninferiority of NAM when compared with SEV treatment in controlling hyperphosphataemia. Secondary objectives were to evaluate the effects of NAM on mineral metabolism and its safety profile.
M A T E R I A L S A N D M E T H O D S

Study setting
NICOREN was a multicentre, open-label, prospective, randomized, comparative, parallel-group, active-controlled study of NAM and SEV in chronic haemodialysis patients with hyperphosphataemia. The study was performed in 18 haemodialysis centres across France. The protocol was approved by a local investigational review board (CPP Nord Ouest II, Amiens, France; reference: 2008-004673-17) and implemented in accordance with the ethical principles of the Declaration of Helsinki (ClinicalTrials.gov registration number: NCT01011699).
End points
The primary end point was to show non-inferiority of NAM when compared with SEV treatment in haemodialysis patients given for the control of elevated serum phosphorus levels. Secondary end points included the evaluation of NAM and SEV safety with measurements of serum 2PY concentrations, and changes in serum levels of total calcium, PTH, 25-OH vitamin D, FGF23 and a-Klotho.
Study design
Following screening, eligible patients completed a washout period to remove their previous phosphate binders, with serum phosphorus being measured every 15 days. The patients stayed in this period until serum phosphorus met the inclusion criteria, within a maximum of 24 weeks. Patients with a serum phosphorus concentration !1.60 mmol/L were randomized to treatment via an interactive system. Randomization was stratified by dialysis centre, gender and statin treatment. Patients were randomized 1 : 1 to receive either NAM (0.5-2 g per day, i.e. 1-4 tablets per day) or SEV hydrochloride (3.2-9.6 g per day, i.e. 4-12 tablets per day). The initiation doses were 0.5 g per day (1 tablet per day) for NAM and 3.2 g per day (4 tablets per day) for SEV. The study comprised a 4-week dose titration period, during which each drug was titrated for efficacy or tolerability. To ensure that changes in serum phosphate levels during the study were due to the study medication and not result of significant changes in dietary phosphate intake, nutritional counselling was given to all patients to limit the intake of diet rich in phosphorus, which included moderate protein intake ($1.2 g/kg/ day). Patients were asked not to change their use of concomitant medications with a possible direct influence on serum phosphorus levels such as vitamin D and calcium binders, as far as possible in accordance with local clinical practice. No patient was treated with active vitamin D sterols or calcimimetics during the study period.
Study population
Written informed consent was obtained before any studyspecific procedures were performed. Eligible patients received long-term haemodialysis treatment three times a week. Furthermore, eligible patients (age 18 years or over) were required to have serum phosphorus levels !1.6 mmol/L, serum total calcium levels 2.37 mmol/L during washout period and serum intact PTH levels between 60 and 800 pg/mL, serum aluminium levels <0.5 mmol/L, serum 25-OH vitamin D levels between 30 and 60 ng/mL, serum albumin levels >30 g/L and platelet counts >150 000/mm 3 . Exclusion criteria included abnormal liver function, autoimmune disease, ongoing chemotherapy and body weight loss >3 kg in the previous 3 months or >6 kg in the previous 6 months.
After enrolment, serum phosphorus and total calcium levels were measured weekly for 24 weeks. Serum uric acid and PTH levels and platelet counts were measured at Weeks 0, 4, 8, 12, 16, 20 and 24 . Serum levels of high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and 25-OH vitamin D were measured at Weeks 0, 12 and 24. Serum phosphorus, total calcium, uric acid and lipid levels, and platelet counts were assayed in an on-site biochemistry laboratory using standard auto-analyser techniques (Modular IIP system; Roche Diagnostics, Basel, Switzerland). Serum intact PTH was determined by a chemiluminometric immunoassay (Liaison N-tact PTH CLIA; Diasorin, Stillwater, MN, USA). For the determinations of 2PY, FGF23 and a-Klotho, serum was centrifuged and then immediately frozen at À80 C prior to analysis at the end of the study in a central laboratory (Amiens University Medical Center, Amiens, France). Serum human C-terminal FGF23 and human soluble a-Klotho were evaluated using ELISA kits (TECOmedical Group, France). Measurements of serum C-terminal human FGF23 and a-Klotho were performed according to instructions provided by Immutopics (intra-assay coefficient of variation: <2.4%, inter-assay coefficient of variation: <4.7%; detection limit of the assay: 1.5 RU/mL) and ImmunoBiological Laboratories (intra-assay coefficient of variation: <3.6%, inter-assay coefficient of variation: <11.4%; detection limit of the assay: 6.15 pg/mL), respectively. The mean 6 standard deviaton (SD) reference values in 30 healthy subjects (mean age: 35.3 6 9.7 years; males: 33%) were 34.3 6 21.8 RU/mL for FGF23 and 1058 6 307 pg/mL for soluble a-Klotho. All readings were performed on an Envision Multiplate Reader (PerkinElmer) at 450 or 620 nm, and against a reagent blank.
An LC-MS/MS assay was developed for the quantitative determination of 2PY levels in human serum. The reference level obtained from the above healthy 30 subjects was 320 6 164 ng/mL. Serum samples were available for only 79 patients. However, these patients did not significantly differ from the entire cohort in terms of age, gender ratio or baseline serum phosphorus levels.
Sample size determination
We estimated that a sample size of 146 patients would provide a power of 80% for demonstrating non-inferiority of NAM (versus SEV), with a predefined non-inferiority margin of 0.20 mmol/L, an SD of 0.43 mmol/L for the primary end point and a two-sided a risk of 0.05. We anticipated a dropout rate of at least 12.5% and thus intended to randomize a total of 180 patients. However, technical and financial problems prevented us from achieving this recruitment target. We subsequently calculated that the 100 randomized patients would yield a power of $70 and 56% for the intention-to-treat (ITT) and the perprotocol analyses (n ¼ 73), respectively.
Statistical analyses
Data are expressed as the mean 6 SD, median (interquartile range) or frequency, as appropriate. Patients were divided into treatment groups. Intergroup comparisons were performed with a v 2 -test (for categorical variables) and Student's t-test or the Mann-Whitney test (for continuous variables). Noninferiority of NAM (relative to SEV) was assessed in terms of the change in mean serum phosphorus levels between baseline and mean values recorded at Weeks 18, 20 and 24. Noninferiority analysis was performed using ITT analysis and perprotocol analysis (as sensitivity analysis) by calculating the onesided 97.5% confidence interval (CI) for the NAM versus SEV difference in the change of serum phosphorus levels. Our choice of the ITT analysis was motived by the higher attrition rate in the NAM arm, which could reduce the baseline comparability of the two arms. The criterion for non-inferiority would have been met when the upper boundary of the one-sided 97.5% CI for the above-described difference was below the predefined non-inferiority margin. To perform the ITT analysis, missing data on serum phosphorus levels at Weeks 18, 20 or 24 were imputed using linear regression models with previous phosphorus levels as predictors. Consequently, half the non-inferiority margin was added to each imputed missing value of the experimental arm to avoid biased values of phosphorus towards equality between the two arms. Thus, all randomized patients could be included in the ITT analysis.
We used a mixed model analysis of variance to assess the within-group changes over time between randomization and Week 24 in the clinical biochemistry parameters. Safety [including reports of adverse events (AEs)] was analysed in each study group. The threshold for statistical significance was set to P 0.05. All statistical analyses were performed using SPSS software (version 18.0, SPSS Inc., Chicago, IL, USA) for Windows (Microsoft Corp., Redmond, WA, USA) or SAS V R software (version 9.2, SAS Institute Inc., Cary, NC, USA).
R E S U L T S
Patient characteristics
In this academic-driven trial, adult chronic haemodialysis patients were recruited from January 2010 to July 2014. Patients were followed up until the last study visit in January 2015. Due to technical and financial problems, the trial was stopped early. This decision was taken by the steering committee.
A total of 100 patients were randomized into the study (NAM: n ¼ 49; SEV: n ¼ 51) and 73 patients completed the entire treatment period (NAM: n ¼ 27; SEV: n ¼ 46). The proportion of study completers was 55% in NAM and 90% in SEV group. The reasons for study discontinuation are summarized in Figure 1 . Tables 1 and 2 describe the demographic, clinical and biochemical characteristics of the patients. Demographic and baseline characteristics were well balanced among the two groups.
Patients allocated to NAM (500 mg tablets) and SEV (800 mg tablets) arms initiated their treatment with, respectively, one and four tablets per day. Mean (6SD) baseline serum phosphorus values in the NAM and SEV groups were, respectively, 2.10 6 0.43 and 2.26 6 0.53 mmol/L. During the titration period, the doses of NAM or SEV were progressively increased. This resulted in a rapid reduction, after 4 weeks, of the mean serum phosphorus level to 1.75 6 0.42 and 1.81 6 0.60 mmol/L in the (Figure 2) . At Week 24, the mean pill burden in the maintenance phase was 2.6 tablets (1.3 g) per day in NAM patients and 10.8 tablets (8.6 g) per day in SEV patients. The overall duration of study drug exposure differed significantly (P < 0.001) between the SEV group (23 6 5 weeks) and the NAM group (17 6 8 weeks) due to different discontinuation rates. This issue is considered in more detail in the safety analysis below.
Primary end point
Efficacy evaluation. The mean decrease in serum phosphorus concentrations from baseline values to average values at Weeks 18, 20 and 24 was 0.40 mmol/L in the SEV group and 0.25 mmol/L in the NAM group. The observed decrease from baseline to Week 24 was significant in both groups (P < 0.001 for the SEV group and P ¼ 0.01 in the NAM group). However, the criterion for non-inferiority of NAM versus SEV was not met: the upper boundary of the 97.5% one-sided CI for the mean difference in serum phosphorus change from baseline to Weeks 18, 20 and 24 was 0.35 mmol/L, which was not below the predefined non-inferiority margin of 0.20 mmol/L. The results of the non-inferiority analysis were the same in the perprotocol as in the ITT set. The disproportionate dropout rate between groups probably explains, at least in part, insufficient power for the demonstration of non-inferiority.
Secondary end points
Safety and compliance. The comparison of treatment discontinuation due to AEs showed a 1.6-fold higher dropout rate in the NAM than in the SEV group during the 24-week treatment period, with a total of 61 serious AEs (Table 3) . Three deaths were recorded during the study, with similar mortality rates in the two groups: 2 of 49 (4%) in the NAM arm (23) 10 ( These fatal events were considered to be related to comorbid conditions, especially cardiovascular complications, rather than to investigational products. The proportion of patients who discontinued treatment due to AEs was much higher in the NAM than in the SEV group (24 versus 4%, respectively; P ¼ 0.05). In both treatment arms, gastrointestinal events accounted for the majority of AEs. In the SEV group, nausea, vomiting and constipation were the most common AEs. In the NAM group, nausea, diarrhoea and thrombocytopenia were the most frequent AEs. In the four cases of thrombocytopenia, mean NAM dosage was 1000 mg/ day, i.e. slightly below the average maintenance dose taken by the patients allocated to the NAM arm. In these patients, a fall in platelet count to <70 000/mm 3 was observed after 4-8 weeks of treatment. It should be noted that the thrombocytopenia resolved rapidly in all four cases after withdrawal of NAM, on average within 4 weeks. As to the other circulating parameters measured, a slight elevation of total alkaline phosphatases (tAP) was observed in both groups, without changes in other liver biochemistry parameters.
Baseline serum 2PY levels were significantly higher in the haemodialysis patients of our study than in healthy control subjects (3495 6 4019 versus 320 6 164 ng/mL, respectively; P < 0.001), with no significant difference between the two treatment arms ( Figure 3A) . However, at Week 24 ( Figure 3B ), serum 2PY levels were more than five times higher in the NAM group compared with the SEV group (21 285 6 17 747 versus 3743 6 5497 ng/mL, P < 0.001).
Effects on biochemical parameters. In the SEV group, we observed significant biochemical changes after 24 weeks of treatment. Serum total calcium concentration increased, whereas serum LDL cholesterol, uric acid and 25-OH vitamin D levels decreased, in addition to serum phosphorus. In the NAM group, serum total calcium and HDL cholesterol levels increased after 24 weeks of treatment, as shown in Table 4 . The table further shows changes in serum biochemistry during the study period by treatment group. The two groups differed significantly with respect to serum HDL and LDL cholesterol levels, and tAP.
C-terminal FGF23 levels were markedly increased at baseline in both treatment arms, relative to the reference range of healthy subjects (P < 0.001). The change in FGF23 levels in response to treatment differed significantly between SEV and NAM groups Figure 4A : they decreased by nearly 50% in the SEV group, whereas they increased by nearly 30% in the NAM group (Table 4 and Figure 4) . Changes in circulating a-Klotho Table 2 . Main circulating biochemical parameters of study participants at baseline Data are reported as the mean 6 SD or (for variables with a non-Gaussian distribution) the median (interquartile range). AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase. a n ¼ 84. The levels decreased from baseline to Week 24 in the NAM group but increased in the SEV group (P < 0.001) ( Figure 4B ), although at baseline, a-Klotho levels were lower in the SEV than in the NAM group. Moreover, the differences remain significant when considering only those patients who completed the trial.
D I S C U S S I O N
The present randomized, comparative clinical trial shows that 24 weeks of treatment with NAM or SEV is effective in significantly reducing serum phosphorus levels in hyperphosphataemic dialysis patients. However, due to the high dropout rate, the study did not have sufficient power to demonstrate noninferiority of NAM in comparison with SEV. Most importantly, AEs were much more frequent in the NAM group than in the SEV group, leading to a strikingly high dropout rate in NAMtreated patients. Moreover, many patients, mostly those in the NAM group, experienced a marked increase in serum 2PY levels. Finally, SEV and NAM exerted different effects on the main Data are reported as the mean 6 SD or (for variables with a non-Gaussian distribution) the median (interquartile range). AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase.
FIGURE 4:
Biochemical changes during the study by treatment arm. Change in the median (interquartile range) serum levels of C-terminal FGF23 (A) and a-Klotho (B) over the study period. *P < 0.0001 for change from baseline to Week 24. hormones and growth factors involved in the regulation of phosphate homeostasis. As regards the significant decrease in serum phosphorus by NAM, the present study confirms previous reports in patients with end-stage renal disease [17] [18] [19] [20] [21] . On the positive side, this theoretically makes NAM with its relatively small, easily accepted pill burden an interesting drug in the control of hyperphosphataemia, in contrast to the majority of bulky phosphate binders with higher pill burden and limited patient acceptance [22] . Reducing pill burden while maintaining efficacy probably increases treatment adherence in patients who are under several other medications as well. In the present NICOREN study, SEV-treated patients took on average four times more tablets per day than those receiving NAM (10.8 versus 2.6, respectively).
Cost-effectiveness is another, potentially positive aspect in favour of NAM when compared with many currently available, calcium-free phosphate binders, although the cost of daily treatments greatly varies from one compound to another. The mean daily dose of NAM (1.3 g) is 20 times cheaper than that of SEV (8.6 g) in France. However, the recent approval of generic SEV will almost certainly lead to a reduction in cost difference.
On the negative side, the proportion of treatment-related AEs was markedly higher in the patients allocated to NAM treatment (24%) than in those allocated to SEV treatment (4%). Four of the NAM group patients developed thrombocytopenia, compared with none in the SEV group, an effect already reported in the literature [19, 23] . This adverse effect may result from a NAM-induced drop in the serum level of thyroxinbinding globulin or one of its derivatives [20] . Note that the thrombocytopenia rapidly resolved in all cases after withdrawal of NAM, on average within 4 weeks. These types of AE(s) may be not present in non-CKD patients using a low dose of NAM (i.e. receiving 500 mg of NAM twice daily), as shown in a recent report on skin-cancer chemoprevention by Chen et al. [24] . Since side effects are a major reason for poor adherence to drugs prescribed to patients with CKD, the NAM-induced adverse effects must be carefully weighed against those caused by phosphate-binding agents.
Another potentially important finding of the present study is that of 2PY accumulation, with an $10-fold increase in serum levels of NAM-treated dialysis patients when compared with 2PY levels of healthy control subjects. Although the massive 2PY accumulation in NAM group patients certainly reflects good treatment adherence in those who did not discontinue the study drug, its potentially adverse clinical impact deserves consideration. In fact, it has been suggested that NAM derivatives are uraemic toxins. By inhibiting the enzyme PARP-1, 2PY may modulate oxidative stress and disturb other cellular processes including the regulation of DNA replication and DNA repair [6, 25] . Recently, PARP inhibitors have been explored in several types of cancer with the goal to induce cell apoptosis [26] [27] [28] . It is noteworthy that these inhibitors frequently induce haematological disorders in a dose-dependent manner, particularly thrombocytopenia. Whether the thrombocytopenia observed in our NAM-treated patients is related to PARP inhibition secondary to 2PY accumulation remains to be evaluated.
Finally, biochemical changes in response to NAM and SEV treatment, respectively, may be indicative of positive or negative effects on patient outcomes. We confirm in the present study another possible benefit of NAM, namely an increase in serum HDL cholesterol, as previously reported by others [29, 30] . NAM increases HDL levels by stimulating apoA1, the main constituent of HDL [31] . The HDL cholesterol increase could be protective against cardiovascular disease including myocardial infarction, sudden death and stroke, which accounts for about half of the mortality in dialysis patients [2, 32] . However, recent trials failed to show a beneficial effect of the niacininduced increase in HDL levels as regards clinical outcomes in the general population [33] [34] [35] . Indeed, niacin administration in addition to statin therapy did not reduce the risk of major vascular events although it did increase the risk of serious AEs [33, 35] .
Several lines of evidence suggest that serum FGF23 is a useful biomarker of, if not, a biological actor in the cardiovascular disease of CKD, with possible changes in response to phosphatetargeted interventions. There are conflicting data on SEV's impact on FGF23 levels [14, 15] . We observed a significant decrease in serum FGF23 levels in SEV-treated patients, in line with several previous controlled studies in CKD patients [13, 36, 37] . Data from animal studies have suggested a NAM effect on FGF23. The administration to CKD rats of an inhibitor of the intestinal sodium-hydrogen exchanger NaPi2b, which also blocked dietary phosphate absorption, was associated with a decrease in FGF23 levels [38] . Similarly, NAM reduced serum FGF23 levels in a murine model of familial tumoral calcinosis [16] . In humans, only one study has shown a small decline (11%) in FGF23 levels in a niacin-treated group (relative to placebo) [39] . In the present study, we failed to observe changes in FGF23 levels in the NAM-treated patients.
Since measurement methods of circulating a-Klotho have become available recently, and only few studies have evaluated the impact of phosphate binders on a-Klotho, we performed a post hoc analysis in the present study, and showed a significant increase in circulating a-Klotho levels in the SEV patient group after 24 weeks of treatment. A different study showed also a significant increase in circulating a-Klotho levels in SEV-treated patients after 48 weeks of treatment [12] . In contrast, a-Klotho levels were significantly decreased following NAM treatment. The impact of NAM on a-Klotho levels has not been investigated previously. This finding and the underlying mechanisms require further investigation.
The present randomized study has several limitations. Firstly, the smaller number of included patients than initially planned and the high dropout rate especially in the NAM group reduced the statistical power of our study. Secondly, the open-label design may have contributed to the high dropout rate in the NAM arm. The patients may have been suspicious of moving to a new treatment (i.e. NAM), relative to standard SEV treatment, and this may have contributed to our failure to meet the criterion of noninferiority. Thirdly, the 24-week treatment period was too short to assess long-term outcomes. Fourthly, we did not perform urine sampling but suppose any residual renal function to be weak due to a long dialysis vintage on average. The strengths of our study include its multicentre, randomized, controlled design, assessment of NAM safety, evaluation of several factors involved in the regulation of phosphorus homeostasis and the finding of massive 2PY accumulation in response to NAM treatment.
In conclusion, a 24-week treatment with NAM significantly decreases phosphorus levels in hyperphosphataemic haemodialysis patients. However, non-inferiority of NAM in comparison with SEV could not be formally demonstrated due to high dropout rates. AEs were more frequent in NAM-than in SEVexposed patients, with treatment discontinuation due to AEs being 1.6 times higher in the NAM group. Even if NAM could be considered as a potentially valuable alternative or a complement to phosphate binder therapy, great caution must be exercised because of its questionable safety profile, with possibly toxic effects of the NAM degradation product 2PY. Future research clearly needs to carefully explore NAM's safety profile further and focus in particular on the effects of 2PY accumulation. Ongoing studies in CKD patients examining the issue of whether a combination of NAM with phosphate binders results in synergistic or additive benefits, or potentially harmful effects, will show whether our concerns are justified or not [40] .
